From L-R: Tune Therapeutics' CSO Derek Jantz, CFO Akira Matsuno and co-founder Charles Gersbach
January 12, 2025 08:00 AM ESTUpdated 06:28 PM
Financing
Cell/Gene Tx

Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic

Andrew Dunn

Senior Biopharma Correspondent

In ge­net­ic med­i­cine, a drum­beat of lay­offs and pipeline cuts has re­placed the ex­cite­ment of just a few years ago, when fresh fi­nanc­ing rounds were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

Tra­vere plans to seek ex­pand­ed la­bel for kid­ney drug de­spite failed tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times